There are two recent developments to report regarding Amarin’s fight to keep generic versions of Vascepa from launching. We discuss the details in today’s article in our Amp biopharma investor forum. A free sign-up* is required, if you have not already signed up. Just click the link below (or paste the URL in your browser if it doesn't open).
*We only use your email for periodic correspondence from Amp about biopharma companies we analyze or for a newsletter that we might send out from time to time.